News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
Editorial Board
For Authors
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice Between the LinesContemporary ConceptsJournalOncViewPodcastsReadout 360Insights from Experts at Mayo Clinic on Translating Evidence to Clinical PracticeOptimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid LeukemiaBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
Editorial Board
For Authors
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Melanoma
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

No Strong Link Between Breast Cancer Risk and Pollutants

September 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

BETHESDA, Maryland-Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.

BETHESDA, Maryland—Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.

The new findings emerged from two studies conducted as part of the Long Island Breast Cancer Study Project, which Congress mandated in 1993. The two studies involved a total of 1,058 women living in Nassau and Suffolk counties on Long Island, which have disproportionately high breast cancer rates, compared with other counties in New York State.

The goal of the two population-based, case-control studies "was to determine whether breast cancer incidence in these two counties was associated with exposures to environmental contaminants," said Marilie D. Gammon, PhD, who served as principal investigator for both studies. "What we observed did not support that possibility strongly." Dr. Gammon is associate professor of epidemiology, University of North Carolina School of Public Health, Chapel Hill.

PAHs result from incomplete combustion. They are inhaled with such things as cigarette smoke and from the smoke and vehicle exhaust that result from burning fossil fuels, and are ingested by eating grilled and smoked foods.

The compounds are potent mammary carcinogens in rodents, and the federal government has designated several of them as probable or possible human carcinogens. However, researchers have not clearly demonstrated carcinogenic effects in the breasts of women.

Organochlorines include several pesticides (such as DDT); the family of industrial compounds known as PCBs; and the termiticide chlordane. DDT was used widely on Long Island to control mosquitoes and gypsy moths before it was banned in 1972. Several previous epidemiologic studies have indicated a link between organochlorine exposure and breast cancer. However, most such studies have not supported an association of DDT and PCBs with the disease.

In the PAH study, Dr. Gammon and her colleagues focused on PAH-DNA adducts—places where the hydrocarbon attaches to the DNA in cells. Adducts serve as markers for exposure to a chemical and are widely believed to indicate tissue damage. The researchers looked for adducts in cells from blood samples donated by 576 women newly diagnosed with breast cancer and 427 women without breast cancer who served as controls.

"The age-adjusted odds ratio for breast cancer in relation to the highest quintile of adduct levels compared to the lowest was 1.51, with little or no evidence of confounding," the researchers reported. However, they found no consistent evidence of an increased risk of breast cancer with increased adduct levels, and no consistent association of adduct levels and two major causes of PAHs—active smoking and inhaling second-hand cigarette smoke, and eating grilled and smoked foods. "The data indicate that PAH-DNA adduct formation may influence breast cancer development, although the association does not appear to be dose dependent and may have a threshold effect," the team concluded.

Said Dr. Gammon, "Our findings suggest that women’s individual responses to similar PAH exposures might be more relevant to breast cancer development than the absolute amount of PAH," and the team is investigating this issue.

Organochlorines Study

For the study of organochlorines, the researchers analyzed blood from 646 women with newly diagnosed breast cancer and from 429 controls for exposure levels to the target chemicals. No substantial elevation in breast cancer risk was found for the lipid-adjusted serum levels between the highest and lowest quintiles for DDT, DDE, chlordane, and dieldrin and other PCBs. No dose-response relations were identified.

A woman’s risk was not increased in relation to organochlorines among those who had not breast-fed, or were overweight, postmenopausal, or long-time Long Island residents. Whether a woman’s breast cancer was diagnosed as invasive or in situ, or whether the tumor was hormone-receptor positive or negative failed to show an association with organochlorine exposure.

The researchers concluded that the results did not support the notion that exposure to organochlorines increases a woman’s risk of breast cancer. However, the study did not exclude the possibility that organochlorines play an early, subtle role in tumor development.

Dr. Gammon noted that some research suggests that the compounds may be related to breast cancers with clinical characteristics associated with poor survival. "We are continuing to investigate this issue among the women in our study," she said. The two reports appeared in the August issue of Cancer Epidemiology, Biomarkers & Prevention.

Articles in this issue

Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Related Videos
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Related Content
Advertisement

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

More Screening Advocacy Is Needed to Improve Breast Cancer Surgery Outcomes

November 27th 2023
Article

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.


Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer

October 30th 2023
Podcast

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.


FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

November 16th 2023
Article

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.


Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.


Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Lack of Vitamin D may Increase Chemo-Induced Neuropathy Risk in Breast Cancer

November 8th 2023
Article

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.


Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

186Re Obisbemeda Earns FDA ODD in Leptomeningeal Metastatic Breast Cancer

November 6th 2023
Article

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

Related Content
Advertisement

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

More Screening Advocacy Is Needed to Improve Breast Cancer Surgery Outcomes

November 27th 2023
Article

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.


Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer

October 30th 2023
Podcast

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.


FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

November 16th 2023
Article

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.


Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.


Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Lack of Vitamin D may Increase Chemo-Induced Neuropathy Risk in Breast Cancer

November 8th 2023
Article

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.


Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

186Re Obisbemeda Earns FDA ODD in Leptomeningeal Metastatic Breast Cancer

November 6th 2023
Article

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.